Compare Pfizer Inc (PFE) vs IAC/Interactivecorp (PPLI) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

PPLI trades at $44.09, down 0.99% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows mixed fundamentals with declining revenue from $5.2B in 2022 to $2.4B in 2025 and negative EPS misses in recent quarters, though net income margin improved to -4.35% from -14.19% in 2024. Recent news highlights potential MGM acquisition talks and upcoming Q2 2026 earnings call on August 4th.

The stock presents a value opportunity with P/B of 0.73 and strong analyst support (63.6% buy rating, $55.40 consensus target), but faces execution risks from consecutive earnings misses and negative cash flow trends. Key catalysts include MGM deal progress and Q2 results, while competitive pressures and volatile profitability remain concerns.